Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of Temsirolimus to Treat Head and Neck Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Signed written informed consent must be given prior to study inclusion~* Histological or cytological confirmed recurrent or metastatic squamous cell carcinoma of the head and neck (HNSCC)~* Measurable progressive disease after platinum-based radiochemotherapy or recurrence or metastatic progressive disease after 1st line platinum-based chemotherapy~* Patients with loco-regional recurrence need to be progression free for at least 6 months after platinum-based radiochemotherapy, if locoregional recurrence is the only lesion~* Cetuximab must have been included in at least one prior line of therapy~* Disease is not amenable to surgery, radiotherapy or platinum-based chemotherapy~* At least one measurable lesion according to RECIST (Version 1.0) criteria~* Age \> 18 years~* ECOG performance status 0-2~* Brain metastases require completion of local therapy with discontinuation of steroids prior to start of treatment~* If of childbearing potential, willingness to use effective contraceptive method (double barrier method) for the study duration and 2 months after last dose~* Willingness and ability to comply with the protocol~* Adequate bone marrow function, liver and renal function~Exclusion Criteria:~* Live expectancy less than 3 months~* Anticancer treatment during the last 30 days prior to start of treatment, including systemic therapy, radiotherapy or major surgery~* Participation in a clinical trial within the last 30 days prior to study treatment~* Serious illness or medical condition other than the disease under study~* Other malignancies within 3 years, with exception of HNSCC, history of a previous basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix~* Inability to potentially complete follow up and treatment per protocol for psychological, familial, sociological or geographical reasons~* Pregnancy or breast feeding~* Known allergic/hypersensitivity reaction to any component of the treatment~* Concurrent treatment with oral anticoagulants~* Uncontrolled diabetes: fasting serum glucose \> 2.0 ULN~* Active or uncontrolled infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Temsirolimus (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).